EUVIMEDDescobrir EUVIMED
EUVIMED · CrossrefJournal

Cancer Chemotherapy and Pharmacology

ISSN 0344-5704 · Springer Science and Business Media LLC

Latest articles

  1. Dose finding, bioavailability, and PK-PD of oral triapine with concurrent chemoradiation for locally advanced cervical cancer and vaginal cancer (ETCTN 9892)

    Sarah E. Taylor, Sarah Behr, Kristine L. Cooper, Haider Mahdi, Denise Fabian, Holly Gallion, Frederick Ueland, John Vargo, Brian Orr, Eugenia Girda, Madeleine Courtney-Brooks, Alexander B. Olawaiye, Leslie M. Randall, Debra L. Richardson, Stephanie A. Sullivan, Marilyn Huang, Susan M. Christner, Sushil Beriwal, Yan Lin, Aman Chauhan, Edward Chu, Elise C. Kohn, Charles Kunos, S. Percy Ivy, Jan H. Beumer

    Published: 2025-12DOI: 10.1007/s00280-024-04720-1

  2. HER-2 SMASH

    Celal Alandağ, Ayşegül Öztürk, Fatih Yulak, Zeynep Deniz Şahin İnan, Mustafa Özkaraca, Burak Batuhan Lacın, Ahmet Altun

    Published: 2025-12DOI: 10.1007/s00280-024-04726-9

  3. Clinical relevance of Nectin-4 downregulation and biological changes caused by cytotoxic chemotherapy in bladder cancer

    Makito Miyake, Takuya Owari, Kota Iida, Sayuri Onishi, Nobutaka Nishimura, Tomomi Fujii, Cynthia N. Jinno, Hideki Furuya, Yuki Oda, Tatsuki Miyamoto, Mitsuru Tomizawa, Takuto Shimizu, Kenta Onishi, Shunta Hori, Yosuke Morizawa, Daisuke Goto, Yasushi Nakai, Nobumichi Tanaka, Noriyoshi Miura, Tadahiko Kikugawa, Takashi Saika, Charles Rosser, Kiyohide Fujimoto

    Published: 2025-12DOI: 10.1007/s00280-025-04783-8

  4. NSABP FC-11: A phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with “quadruple wild-type” (KRAS/NRAS/BRAF/PIK3CA) metastatic colorectal cancer based on HER2 status: amplified, non-amplified (wild-type), or mutated

    Tanner J. Freeman, Thomas J. George, Samuel A. Jacobs, Greg Yothers, Tatjana Kolevska, Huichen Feng, Corey Lipchik, Sai Maley, Nan Song, Ashok Srinivasan, Melanie Finnigan, James L. Wade, Gary L. Buchschacher, Tareq Al baghdadi, Asheesh Shipstone, Daniel Lin, Shannon L. Puhalla, Carmen J. Allegra, Norman Wolmark, Katherine L. Pogue-Geile

    Published: 2025-12DOI: 10.1007/s00280-025-04802-8

Volumes

2025 · 1252024 · 1352023 · 982022 · 1332021 · 1812020 · 2012019 · 2612018 · 2362017 · 2682016 · 2822015 · 2872014 · 2882013 · 3312012 · 2872011 · 3602010 · 2512009 · 2982008 · 2382007 · 1972006 · 2702005 · 1772004 · 1802003 · 1602002 · 1502001 · 1882000 · 1691999 · 1851998 · 1331997 · 1871996 · 2091995 · 3401994 · 4061993 · 1781992 · 2591991 · 1781990 · 2371989 · 2791988 · 1441987 · 1771986 · 213

Conhecimento que se adapta ao seu trabalho.

Do início gratuito e da pesquisa bibliográfica pessoal até à Research Suite completa.

Ver tarifas →

Todos os textos integrais das editoras estão incluídos?

Não. As referências bibliográficas, os resumos e os textos integrais são conteúdos diferentes. A disponibilidade de um texto integral depende da fonte, do Open Access e das licenças de que já dispõe. Um plano EUVIMED não substitui direitos adicionais de editor.